Bulk Pharmaceutical API Sources for INTRAROSA

Bulk Pharmaceutical API Sources for INTRAROSA

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		D4000_SIGMA
Biosynth		D-0340
TCI (Tokyo Chemical Industry)		D0044

Bulk Active Pharmaceutical Ingredient (API) Sources for INTRAROSA

Last updated: July 29, 2025

Introduction

INTRAROSA (buprenorphine transdermal system) is a prescription medication used predominantly for managing opioid dependence and pain management. Its effectiveness hinges on the consistent delivery of buprenorphine, a potent partial opioid agonist. The manufacturing integrity, including the quality and sourcing of the Active Pharmaceutical Ingredient (API), is critical to ensure safety, efficacy, and regulatory compliance. This report explores the primary sources of bulk buprenorphine API for INTRAROSA, emphasizing key manufacturers, quality standards, and supply chain considerations.

Overview of Buprenorphine API Production

Buprenorphine, a semi-synthetic opioid, is produced via complex chemical synthesis processes that require specialized expertise and stringent quality control. Major API suppliers operate under Good Manufacturing Practice (GMP) standards, ensuring products meet international safety and potency specifications. The supply chain involves key geographical regions—mainly China, India, and Europe—each with prominent manufacturers known for their capacity, quality, and regulatory compliance.

Leading API Manufacturers for Buprenorphine

1. Ind-Swift Laboratories Ltd. (India)

Ind-Swift is a prominent pharmaceutical company specializing in active ingredients, including buprenorphine. Known for robust GMP compliance, their API manufacturing facilities are certified by global regulatory agencies like the US FDA and European EMA. Ind-Swift's API offerings for buprenorphine are widely used in generic formulations, including transdermal systems like INTRAROSA.

2. Sun Pharmaceutical Industries Ltd. (India)

As one of India’s largest pharmaceutical firms, Sun Pharma produces high-quality buprenorphine APIs. Their manufacturing plants employ advanced synthesis technologies and quality assurance processes conformant with international standards. Their APIs often serve both domestic and global markets, including opioid substitution therapies.

3. Zhangzhou Pharmaceutical Co., Ltd. (China)

Chinese manufacturers have become key players in buprenorphine API production, with Zhangzhou Pharmaceutical among the leading entities. Their APIs are used globally, including in generic transdermal formulations. The company adheres to GMP standards, although regulatory approvals vary by region, making due diligence essential.

4. Bilcare Ltd. (India)

Known primarily as a packaging and supply chain solutions provider, Bilcare also engages in API sourcing, often facilitating APIs from multiple manufacturers to ensure supply security for global pharmaceutical clients.

5. Praxair (now part of Linde PLC)

In specialty gas supply, Praxair provides certain chemical precursors involved in API synthesis, though it does not manufacture buprenorphine directly. However, supply chain services and quality gases are integral to API production processes.

6. Contract Manufacturing Organizations (CMOs)

Numerous CMOs across India and China, such as Jubilant Life Sciences and Zhejiang Huahai Pharmaceutical, also produce buprenorphine APIs under strict regulatory oversight. Their capacity to scale production and maintain consistent quality makes them vital to supply chains.

Quality and Regulatory Standards

API suppliers for INTRAROSA must meet rigorous quality standards tailored to controlled substances. This includes adherence to:

• Good Manufacturing Practice (GMP): Ensures APIs are produced consistently under controlled conditions to meet quality specifications ([1]).

• Controlled Substance Regulations: Buprenorphine is classified as a Schedule III controlled substance in the U.S., necessitating strict compliance with DEA regulations ([2]).

• International Certifications: ISO certifications, US FDA approvals, and EMA certifications are critical indicators of quality assurance.

• Analytical and Stability Testing: Comprehensive testing (e.g., HPLC, LC-MS/MS) for potency, impurities, residual solvents, and stability under storage conditions.

Supply Chain and Sourcing Considerations

• Geographical Diversification: To mitigate risks associated with regional regulations or disruptions, manufacturers often diversify API sourcing across multiple regions.

• Transparency and Traceability: Ensuring traceability from raw material origin to final API batch is paramount for compliance and quality assurance.

• Pricing and Lead Times: The proximity of the API manufacturer impacts manufacturing timelines and costs, with Indian and Chinese sources offering competitive pricing and substantial capacities.

• Regulatory Challenges: Some Chinese API producers face scrutiny due to past compliance issues, emphasizing the need for due diligence when selecting suppliers.

Impact on INTRAROSA Manufacturing

The quality and consistency of buprenorphine API directly influence INTRAROSA's safety profile and therapeutic outcomes. The drug's transdermal delivery system particularly demands APIs with high purity and stability to prevent skin irritation, dosage inconsistency, or adverse effects. Manufacturers sourcing APIs from certified suppliers with proven track records enhance the product’s regulatory compliance and market acceptance.

Emerging Trends and Future Outlook

• Vertical Integration: Some pharmaceutical companies are investing in building in-house API manufacturing facilities to ensure quality and secure supply.

• Biotechnological Advances: Despite traditional chemical synthesis dominating buprenorphine production, biotechnological methods are under exploring for potential improvements in purity and yield.

• Sustainability and Green Chemistry: Emphasis on environmentally sustainable production methods is increasing, influencing future API manufacturing standards.

Key Challenges in API Sourcing

• Regulatory Variability: Differing standards and approval processes across regions can impact supply assurance.

• Intellectual Property Rights: Proprietary synthesis processes may limit the number of licensed API manufacturers.

• Supply Disruptions: Political, environmental, or logistical issues in key regions can hamper API availability.

Conclusion

The procurement of bulk buprenorphine API for INTRAROSA involves a complex landscape of reputable manufacturers, stringent quality standards, and dynamic supply chain factors. India and China dominate the API manufacturing sector, with companies like Ind-Swift, Sun Pharma, and Zhangzhou Pharmaceutical leading the market. Ensuring API sourcing from FDA- and EMA-compliant producers with verified traceability and quality controls is essential for maintaining product integrity. As the market evolves, increased emphasis on supply security, regulatory compliance, and sustainable practices will shape the API sourcing strategies for transdermal buprenorphine products.

---

Key Takeaways

• The primary APIs for INTRAROSA are supplied predominantly by Indian and Chinese manufacturers, with notable players like Ind-Swift and Zhangzhou Pharmaceutical.

• Rigorous adherence to GMP and international regulatory standards is essential for API suppliers due to the controlled substance nature of buprenorphine.

• Diversifying sources and ensuring traceability mitigate supply risks and support regulatory compliance.

• Trends toward in-house API production and environmentally sustainable methods are shaping the future of buprenorphine manufacturing.

• Vigilant due diligence on supplier certifications and quality assurances is fundamental to safeguard product efficacy and patient safety.

---

FAQs

1. What are the main regions producing buprenorphine API for INTRAROSA?
Primarily India and China serve as the main regions supplying buprenorphine API to the global market, including manufacturers supplying to INTRAROSA.

2. How do quality standards impact API sourcing for buprenorphine?
High-quality production adhering to GMP, regulatory approvals, and robust testing ensures API efficacy, safety, and regulatory compliance, directly affecting INTRAROSA's performance.

3. Are there certified alternative API sources for buprenorphine?
Yes, several certified manufacturers in India and China, such as Sun Pharma and Zhangzhou Pharmaceutical, supply certified APIs. However, due diligence is essential due to the controlled substance classification.

4. What risks are associated with API sourcing for buprenorphine?
Risks include supply disruptions, regulatory non-compliance, variability in API purity, and potential intellectual property issues.

5. What trends are shaping future API sourcing for opioid medications like INTRAROSA?
Emerging trends involve increased vertical integration, biotechnological innovations, focus on sustainability, and enhanced supply chain transparency.

---

Sources

[1] World Health Organization. Good Manufacturing Practices (GMP) for Pharmaceuticals.
[2] U.S. Drug Enforcement Administration. Control of Substances Listed in Schedules I and II of the Controlled Substances Act.